Biologics supplier for aesthetic practices in Fort Collins, CO

Cold-chain logistics for aesthetic practices

Medspas and aesthetic practices that stock injectable-adjacent biologics for the first time often need to set up a dedicated cold-chain receiving process. Cryopreserved Wharton's jelly and exosome products are shipped overnight on dry ice in a validated container and are stored at -80 degrees C until use.

Lyophilized formats, by contrast, are shelf-stable under normal storage conditions and are reconstituted according to the insert included with each lot, which can simplify inventory for a smaller practice without freezer capacity.

Documentation before you stock a product

Before adding any product to inventory, a practice can request the certificate of analysis, donor eligibility summary, and lot release record for the specific lot being considered, along with the supplier's processing description.

For exosome products specifically, supplier-reported characterization data, including particle concentration and marker testing, is available to verified accounts so a medical director can review the analytical record directly.

• Certificate of analysis
• Donor eligibility summary
• Lot release record
• Processing description
• Exosome characterization data where applicable

NPI-verified accounts for medspas

Because many medspas operate under a supervising physician rather than a facility-level NPI, account setup confirms the NPI number of the supervising physician or medical director associated with the practice.

This keeps ordering authority tied to a licensed individual and gives the practice a clear record for any later compliance review of its vendor relationships.

Confirming your regulatory posture

Precision Biologics does not advise on treatment protocols, dosing, or which product fits a specific aesthetic use. Those determinations rest with the supervising physician and the practice's own legal counsel.

We recommend confirming open regulatory questions directly with the Colorado medical board. Verified accounts can also schedule a physician-level conversation about product documentation through their account representative.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.